EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PCSK9 in Cancer: Biological Mechanisms and Implications for Therapeutic Resistance

Nuriza Ulul Azmi iD, Rezi Riadhi Syahdi iD, Meidi Utami Puteri iD, Arry Yanuar iD, Mitsuyasu Kato iD, Fadlina Chany Saputri iD

Biomolecules · 31.12.2025 · 16 (1) · 67

DOI: 10.3390/biom16010067 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 31.12.2025. Verfasst von Nuriza Ulul Azmi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitas Indonesia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains a major global health challenge, largely due to its biological heterogeneity and the capacity of tumor cells to adapt under metabolic and environmental stress. Lipid metabolism has increasingly been recognized as a contributor to tumor progression and treatment response. Proprotein convertase subtilisin/kexin type 9 (PCSK9), widely known for regulating low-density lipoprotein (LDL) receptor turnover and systemic cholesterol levels, has recently been implicated in cancer biology. Emerging evidence shows that PCSK9 influences processes such as cell survival, MHC-I-mediated immune recognition, membrane receptor trafficking, and cellular stress responses, indicating roles that extend beyond its canonical metabolic function. These mechanisms also raise the potential relevance of PCSK9 to affect treatment tolerance and drug responsiveness. This review summarizes current knowledge on the biological functions of PCSK9 in cancer and examines how these pathways may have implications for therapeutic resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proprotein Convertase 9NeoplasmsDrug Resistance, NeoplasmHumansLipid MetabolismAnimals

Stichwörter der Autor:innen

PCSK9cancerchemoresistancehypercholesterolemialipid metabolism

Substanzen

Proprotein Convertase 9PCSK9 protein, human

Autor:innen und Institutionen

  • Department of Experimental Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI Depok, Depok 16424, Indonesia.
  • Biomedical Computation and Drug Design Laboratory, Faculty of Pharmacy, Universitas Indonesia, Kampus UI Depok, Depok 16424, Indonesia.
  • National Metabolomics Collaborative Research Centre, Faculty of Pharmacy, Universitas Indonesia, Kampus UI Depok, Depok 16424, Indonesia.
  • Faculty of Pharmacy, Universitas Indonesia, Kampus UI Depok, Depok 16424, Indonesia.

ORCID-Profile: Nuriza Ulul Azmi, Rezi Riadhi Syahdi, Meidi Utami Puteri, Arry Yanuar, Mitsuyasu Kato, Fadlina Chany Saputri

Förderung

  • Universitas Indonesia

Zitieren

APA

Azmi, N. U., Syahdi, R. R., Puteri, M. U., Yanuar, A., Kato, M., & Saputri, F. C. (2025). PCSK9 in Cancer: Biological Mechanisms and Implications for Therapeutic Resistance. Biomolecules, 16(1), 67. https://doi.org/10.3390/biom16010067

Vancouver

Azmi NU, Syahdi RR, Puteri MU, Yanuar A, Kato M, Saputri FC. PCSK9 in Cancer: Biological Mechanisms and Implications for Therapeutic Resistance. Biomolecules. 2025;16(1):67. doi:10.3390/biom16010067

BibTeX
@article{Azmi2025,
  author = {Azmi, Nuriza Ulul and Syahdi, Rezi Riadhi and Puteri, Meidi Utami and Yanuar, Arry and Kato, Mitsuyasu and Saputri, Fadlina Chany},
  title = {PCSK9 in Cancer: Biological Mechanisms and Implications for Therapeutic Resistance},
  journal = {Biomolecules},
  year = {2025},
  volume = {16},
  number = {1},
  pages = {67},
  doi = {10.3390/biom16010067}
}
Kostenlos starten →